These data support the use of sacituzumab plus pembrolizumab as a potential new standard of care,” said Sara Tolaney, MD.

Sacituzumab tirumotecan showed “promising efficacy” regardless of PD-L1 status, said study presenter Yongmei Yin, MD, PhD.

CHICAGO -- Treatment with single-agent sacituzumab govitecan (Trodelvy) offered no survival advantage over docetaxel in patients with advanced non-small-cell lung cancer (NSCLC) previously treated ...

Overall, we found that when we administered sacituzumab at 10 mg/kg, on days 1 and 8, that the response rates were approximately 32% in these patients. No new safety signals were identified.

Sacituzumab govitecan induced durable responses in patients with heavily pretreated metastatic triple-negative breast cancer, according to results of a phase 1/2 single-group trial published in ...

Immunomedics is currently evaluating sacituzumab govitecan in the phase II TROPHY-U-01 study for addressing patients with mUC. In October 2019, the company presented interim data at the European ...

Researchers who conducted a real-world analysis of trastuzumab deruxtecan found the drug to be effective in treating metastatic breast cancer, though survival outcomes did not reach clinical trial ...

There is a synthetic lethality between sacituzumab govitecan and a PARP inhibitor, noted Aditya Bardia, MBBS, MPH, breast medical oncologist, Massachusetts General Hospital, Harvard Medical School.

Study of sacituzumab govitecan-hziy versus treatment of physician's choice in participants with HR+/HER2- metastatic breast cancer (TROPiCS-02). ClinicalTrials.gov. Updated November 18, 2023 ...

Gilead is continuing to explore sacituzumab govitecan in other phase 3 trials, including ASCENT-07 (ClinicalTrials.gov Identifier: NCT05840211) for hormone receptor–positive, human epidermal ...

Sacituzumab govitecan and pembrolizumab can produce a high response rate in previously treated, advanced urothelial carcinoma, according to researchers. Sacituzumab govitecan and pembrolizumab can ...

Immunomedics, Inc. IMMU announced that the FDA has granted a Fast Track designation to its lead candidate sacituzumab govitecan for the treatment of adult patients with locally advanced or ...